Table Of Contents :
Table of Contents 2
List of Tables 12
List of Figures 14
Introduction 15
Global Markets Direct Report Coverage 15
Staphylococcus Aureus Infections Overview 16
Therapeutics Development 17
An Overview of Pipeline Products for Staphylococcus Aureus Infections 17
Staphylococcus Aureus Infections Therapeutics under Development by Companies 19
Staphylococcus Aureus Infections Therapeutics under Investigation by Universities/Institutes 23
Late Stage Products 25
Comparative Analysis 25
Mid Clinical Stage Products 26
Comparative Analysis 26
Early Clinical Stage Products 27
Comparative Analysis 27
Discovery and Pre-Clinical Stage Products 28
Comparative Analysis 28
Staphylococcus Aureus Infections Therapeutics - Products under Development by Companies 29
Staphylococcus Aureus Infections Therapeutics - Products under Investigation by Universities/Institutes 35
Companies Involved in Staphylococcus Aureus Infections Therapeutics Development 36
F. Hoffmann-La Roche Ltd. 36
United Therapeutics Corporation 36
Sanofi-Aventis 37
AstraZeneca PLC 37
GlaxoSmithKline plc 38
Nektar Therapeutics 38
Merck & Co., Inc. 39
Takeda Pharmaceutical Company Limited 39
Rib-X Pharmaceuticals, Inc. 40
Achillion Pharmaceuticals, Inc. 40
BioMarin Pharmaceutical Inc. 41
Forest Laboratories, Inc. 41
Pfizer Inc. 42
Toyama Chemical Co. Ltd 42
Warner Chilcott Limited 43
Wockhardt Limited 43
Optimer Pharmaceuticals, Inc. 44
Paratek Pharmaceuticals, Inc. 44
Helix BioMedix, Inc. 45
Immtech Pharmaceuticals, Inc. 45
Lorus Therapeutics Inc 46
Basilea Pharmaceutica Ltd. 46
Biota Holdings Limited 47
Oragenics, Inc. 47
CytoGenix, Inc. 48
Advanced Life Sciences Holdings, Inc. 48
Symbollon Pharmaceuticals, Inc. 49
Theravance, Inc. 49
CrystalGenomics, Inc. 50
Phynova Group Ltd 50
Syntopix Group Plc 51
PolyMedix, Inc. 51
e-Therapeutics plc 52
Piramal Life Sciences Limited 52
Bharat Biotech International Limited 53
Immupharma Plc 53
MerLion Pharmaceuticals Pte Ltd 55
Evolva SA 55
GlycoVaxyn AG 56
MicuRx Pharmaceuticals, Inc. 56
Destiny Pharma Ltd. 57
Nitric Biotherapeutics, Inc. 57
Kenta Biotech Ltd. 58
aRigen Pharmaceuticals, Inc. 58
Nabriva Therapeutics AG 59
Concert Pharmaceuticals, Inc. 59
Inimex Pharmaceuticals, Inc. 60
NanoBio Corporation 60
Enanta Pharmaceuticals, Inc. 61
Trius Therapeutics, Inc. 61
Lytix Biopharma AS 62
Medisyn Technologies, Inc. 62
PALUMED S.A. 63
Staphylococcus Aureus Infections - Therapeutics Assessment 64
Assessment by Monotherapy Products 64
Assessment by Combination Products 65
Assessment by Route of Administration 66
Assessment by Molecule Type 68
Late Stage Drug Profiles 70
AR-2474 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
HB1345 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
LOR-220 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
GSK945237 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
NKTR-063 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Restanza - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Lysostaphin - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Teflaro - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Omadacycline - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
PYN6 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
LT-29 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
WAP-8294A2 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
PMX-30063 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
PMX-70004 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
CY403 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
MX-2401 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
TD-1792 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Drug for Bacterial Infections - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
MU1140 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Nasodine - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
BC-3205 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
KBSA302 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
BC-3781 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
BC-7013 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Delafloxacin - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
RX-02 Program - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
KBSA301 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
C-20081 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
XF 73 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
S. Aureus Antibodies - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Lipopetide Program - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
CG400549 - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
WCK 771 - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
Community MRSA Program - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
TAKSTA - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
PM181104 - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
Vancomyquin - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
Cephaloquine - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
IMX942 - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
ETX1153a - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
ETX1153a - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
ETX1153b - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
CDI Program - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
Torezolid - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
Lipopeptide Program - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
EDP-322 - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
Nemonoxacin - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
Phytobacx - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
MRX-I - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
Lytixar - Drug Profile 127
Product Description 127
Mechanism of Action 127
R&D Progress 127
MK-3009 - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
Cotrimoxazole - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
SYN 0017 - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 130
SYN 0096 - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
Vancomycin + Calcium alginate - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
Rifabutin + Trimethoprim - Sulfamethoxazole - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
SA3Ag Vaccine - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
GSK2392106A - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
ABI-0043 - Drug Profile 136
Product Description 136
Mechanism of Action 136
R&D Progress 136
Nitric Oxide - Drug Profile 137
Product Description 137
Mechanism of Action 137
R&D Progress 137
Ceftobiprole. - Drug Profile 139
Product Description 139
Mechanism of Action 139
R&D Progress 139
IPP-203101 - Drug Profile 141
Product Description 141
Mechanism of Action 141
R&D Progress 141
CEF104 - Drug Profile 142
Product Description 142
Mechanism of Action 142
R&D Progress 142
AZD9742 - Drug Profile 143
Product Description 143
Mechanism of Action 143
R&D Progress 143
Altabax - Drug Profile 144
Product Description 144
Mechanism of Action 144
R&D Progress 144
Trimethoprim + sulfamethoxazole + Cephalexin - Drug Profile 145
Product Description 145
Mechanism of Action 145
R&D Progress 145
Trimethoprim + sulfamethoxazole + Clindamycin - Drug Profile 146
Product Description 146
Mechanism of Action 146
R&D Progress 146
Daptomycin - Drug Profile 147
Product Description 147
Mechanism of Action 147
R&D Progress 147
GSK2392105A - Drug Profile 148
Product Description 148
Mechanism of Action 148
R&D Progress 148
WCK 2370 - Drug Profile 149
Product Description 149
Mechanism of Action 149
R&D Progress 149
WCK 2349 - Drug Profile 150
Product Description 150
Mechanism of Action 150
R&D Progress 150
WCK 2664 - Drug Profile 151
Product Description 151
Mechanism of Action 151
R&D Progress 151
SAR 279356 - Drug Profile 152
Product Description 152
Mechanism of Action 152
R&D Progress 152
T-3912 - Drug Profile 153
Product Description 153
Mechanism of Action 153
R&D Progress 153
Staphylococcus Aureus Vaccine - Drug Profile 154
Product Description 154
Mechanism of Action 154
R&D Progress 154
Drug For MRSA - Drug Profile 155
Product Description 155
Mechanism of Action 155
R&D Progress 155
Systemic Antibiotic - Drug Profile 156
Product Description 156
Mechanism of Action 156
R&D Progress 156
Topical Antibiotic - Drug Profile 157
Product Description 157
Mechanism of Action 157
R&D Progress 157
ACH-2881 - Drug Profile 158
Product Description 158
Mechanism of Action 158
R&D Progress 158
DasKloster 0138–01 - Drug Profile 159
Product Description 159
Mechanism of Action 159
R&D Progress 159
AMR-BAC-1 - Drug Profile 160
Product Description 160
Mechanism of Action 160
R&D Progress 160
AMR-BAC-2 - Drug Profile 161
Product Description 161
Mechanism of Action 161
R&D Progress 161
AMR-BAC-3 - Drug Profile 162
Product Description 162
Mechanism of Action 162
R&D Progress 162
Drug For MRSA - Drug Profile 163
Product Description 163
Mechanism of Action 163
R&D Progress 163
SLP0905 - Drug Profile 164
Product Description 164
Mechanism of Action 164
R&D Progress 164
SLP0906 - Drug Profile 166
Product Description 166
Mechanism of Action 166
R&D Progress 166
SLP1003 - Drug Profile 168
Product Description 168
Mechanism of Action 168
R&D Progress 168
SLP0904 - Drug Profile 170
Product Description 170
Mechanism of Action 170
R&D Progress 170
SLP1004 - Drug Profile 172
Product Description 172
Mechanism of Action 172
R&D Progress 172
Vancomycin - Drug Profile 174
Product Description 174
Mechanism of Action 174
R&D Progress 174
Staphylococcus Aureus Infections Therapeutics – Drug Profile Updates 175
Staphylococcus Aureus Infections Therapeutics - Discontinued Products 182
Staphylococcus Aureus Infections - Featured News 183
May 26, 2011: Lytix Biopharma Announces Successful Completion Of Two Phase I/IIa Studies Of Lytixar 183
May 26, 2011: Lytix Biopharma Announces Successful Completion Of Two Phase I/IIa Studies Of Lytixar 183
May 11, 2011: CrystalGenomics Completes Phase I MAD Study of Novel Antibiotic Candidate CG400549, And Prepares For Phase II Clinical Study 184
May 09, 2011: Basilea Presents New Data On Ceftobiprole 184
May 09, 2011: Inhibitex Announces Staphylococcus Aureus Investigational Vaccine Elicits Positive Immune Response In Phase I Study 185
Apr 18, 2011: Nabriva Reports Positive Results from Phase II Trial Of Pleuromutilin Antibiotic BC-3781 In ABSSSI 185
Apr 11, 2011: Trius Announces Patent Term Extension For Torezolid Phosphate 186
Apr 11, 2011: Merck Provides Update On Phase II/III Clinical Trial Of V710 187
Feb 24, 2011: PolyMedix Successfully Completes Phase I Exposure Escalation Safety Study With PMX-30063 Antibiotic 187
Nov 10, 2010: Furiex Reports Positive Phase II Results For JNJ-Q2 In Complicated Skin Infections 188
Appendix 190
Methodology 190
Coverage 190
Secondary Research 190
Primary Research 190
Expert Panel Validation 191
Contact Us 191
Disclaimer 191"
List of Tables
Number of Products Under Development for Staphylococcus Aureus Infections, Q2 2011 17
Products under Development for Staphylococcus Aureus Infections – Comparative Analysis, Q2 2011 18
Number of Products under Development by Companies, Q2 2011 20
Number of Products under Development by Companies, Q2 2011 21
Number of Products under Development by Companies, Q2 2011 22
Number of Products under Investigation by Universities/Institutes, Q2 2011 24
Comparative Analysis by Late Stage Development, Q2 2011 25
Comparative Analysis by Mid Clinical Stage Development, Q2 2011 26
Comparative Analysis by Early Clinical Stage Development, Q2 2011 27
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q2 2011 28
Products under Development by Companies, Q2 2011 29
Products under Development by Companies, Q2 2011 30
Products under Development by Companies, Q2 2011 31
Products under Development by Companies, Q2 2011 32
Products under Development by Companies, Q2 2011 33
Products under Development by Companies, Q2 2011 34
Products under Investigation by Universities/Institutes, Q2 2011 35
F. Hoffmann-La Roche Ltd., 2011 36
United Therapeutics Corporation, 2011 36
Sanofi-Aventis, 2011 37
AstraZeneca PLC, 2011 37
GlaxoSmithKline plc, 2011 38
Nektar Therapeutics, 2011 38
Merck & Co., Inc., 2011 39
Takeda Pharmaceutical Company Limited, 2011 39
Rib-X Pharmaceuticals, Inc., 2011 40
Achillion Pharmaceuticals, Inc., 2011 40
BioMarin Pharmaceutical Inc., 2011 41
Forest Laboratories, Inc., 2011 41
Pfizer Inc., 2011 42
Toyama Chemical Co. Ltd, 2011 42
Warner Chilcott Limited, 2011 43
Wockhardt Limited, 2011 43
Optimer Pharmaceuticals, Inc., 2011 44
Paratek Pharmaceuticals, Inc., 2011 44
Helix BioMedix, Inc., 2011 45
Immtech Pharmaceuticals, Inc., 2011 45
Lorus Therapeutics Inc, 2011 46
Basilea Pharmaceutica Ltd., 2011 46
Biota Holdings Limited, 2011 47
Oragenics, Inc., 2011 47
CytoGenix, Inc., 2011 48
Advanced Life Sciences Holdings, Inc., 2011 48
Symbollon Pharmaceuticals, Inc., 2011 49
Theravance, Inc., 2011 49
CrystalGenomics, Inc., 2011 50
Phynova Group Ltd, 2011 50
Syntopix Group Plc, 2011 51
PolyMedix, Inc., 2011 51
e-Therapeutics plc, 2011 52
Piramal Life Sciences Limited, 2011 52
Bharat Biotech International Limited, 2011 53
Immupharma Plc, 2011 54
MerLion Pharmaceuticals Pte Ltd, 2011 55
Evolva SA, 2011 55
GlycoVaxyn AG, 2011 56
MicuRx Pharmaceuticals, Inc., 2011 56
Destiny Pharma Ltd., 2011 57
Nitric Biotherapeutics, Inc., 2011 57
Kenta Biotech Ltd., 2011 58
aRigen Pharmaceuticals, Inc., 2011 58
Nabriva Therapeutics AG, 2011 59
Concert Pharmaceuticals, Inc., 2011 59
Inimex Pharmaceuticals, Inc., 2011 60
NanoBio Corporation, 2011 60
Enanta Pharmaceuticals, Inc., 2011 61
Trius Therapeutics, Inc., 2011 61
Lytix Biopharma AS, 2011 62
Medisyn Technologies, Inc., 2011 62
PALUMED S.A., 2011 63
Assessment by Monotherapy Products, Q2 2011 64
Assessment by Combination Products 65
Assessment by Stage and Route of Administration, Q2 2011 67
Assessment by Molecule Type, Q2 2011 69
Staphylococcus Aureus Infections Therapeutics – Drug Profile Updates 175
Discontinued Products 182"
List of Figures
Number of Products under Development for Staphylococcus Aureus Infections, Q2 2011 17
Products under Development for Staphylococcus Aureus Infections – Comparative Analysis, Q2 2011 18
Products under Development by Companies, Q2 2011 19
Products under Investigation by Universities/Institutes, Q2 2011 23
Late Stage Products, Q2 2011 25
Mid Clinical Stage Products, Q2 2011 26
Early Clinical Stage Products, Q2 2011 27
Discovery and Pre-Clinical Stage Products, Q2 2011 28
Assessment by Monotherapy Products, Q2 2011 64
Assessment by Combination Products, Q2 2011 65
Assessment by Route of Administration, Q2 2011 66
Assessment by Stage and Route of Administration, Q2 2011 67
Assessment by Molecule Type, Q2 2011 68
Assessment by Stage and Molecule Type, Q2 2011 69
|
